fap-2286
mAbexperimentalImaging agent
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 14, 2020 (NCT04621435)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibroblast activation protein alphaINHIBITOR
FAP inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07144085 | Phase 1 | Sep 30, 2025 | China Medical University |
| NCT05180162 | Phase 1 | Dec 9, 2021 | Clovis Oncology, University of California, San Francisco |
| NCT04939610 | Phase 1/Phase 2 (Phase 2) | Jul 30, 2021 | Clovis Oncology, University of California, San Francisco |
| NCT04621435 | Phase 1 | Dec 14, 2020 | Clovis Oncology, University of California, San Francisco |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clovis Oncology | For profit | 3 | 1 | 2 | 2020 |
| University of California, San Francisco | Academic/Hospital | 3 | 2 | 2 | 2020 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1